Advertisement

Nuclear Medicine and Molecular Imaging

, Volume 50, Issue 1, pp 24–30 | Cite as

Correlation between Semi-Quantitative 18F-FDG PET/CT Parameters and Ki-67 Expression in Small Cell Lung Cancer

  • Soyeon Park
  • Eunsub Lee
  • Seunghong Rhee
  • Jaehyuk Cho
  • Sunju Choi
  • Sinae Lee
  • Jae Seon Eo
  • Kisoo Pahk
  • Jae Gol Choe
  • Sungeun KimEmail author
Original Article

Abstract

Purpose

The aim of this study was to evaluate the relationship between semiquantitative parameters on 18F-FDG PET/CT including maximum standardized uptake value (SUVmax), mean standardized uptake value (SUVmean), metabolic tumor volume (MTV), and total lesion glycolysis (TLG) and the expression level of Ki-67 in small-cell lung cancer (SCLC).

Methods

Ninety-four consecutive patients with SCLC were enrolled in this study. They underwent 18F-FDG PET/CT for initial evaluation of SCLC, and we measured SUVmax, avgSUVmean, MTVsum, and TLGtotal on 18F-FDG PET/CT images. The protein expression of Ki-67 was examined by immunohistochemical staining.

Results

Significant correlations were found between the MTVsum and Ki-67 labeling index (r = 0.254, p = 0.014) and the TLGtotal and Ki-67 labeling index (r = 0.239, p = 0.020). No correlation was found between the SUVmax and Ki-67 labeling index (r = 0.116, p = 0.264) and the avgSUVmean and Ki-67 labeling index (r = 0.031, p = 0.770). Dividing the Ki-67 expression level into three categories, it was suggested that increasing Ki-67 expression level caused a stepwise increase in the MTVsum and TLGtotal. (p = 0.028 and 0.039, respectively), but not the SUVmax and avgSUVmean (p = 0.526 and 0.729, respectively).

Conclusion

In conclusion, the volume-based parameters of 18F-FDG PET/CT correlate with immunohistochemical staining of Ki-67 in SCLC. Measurement of the MTVsum and TLGtotal by 18F-FDG PET/CT might be a simple, noninvasive, and useful method to determine the proliferative potential of cancer cells.

Keywords

Small-cell lung carcinoma 18F-FDG PET/CT Metabolic tumor volume Ki-67 

Notes

Acknowledgments

This study was funded by a Korea University Special Research grant, Korea University, Seoul, South Korea (no. K1507831).

Compliance with ethical standards

Conflict of Interest

Soyeon Park, Eunsub Lee, Seunghong Rhee, Jaehyuk Cho, Sunju Choi, Sinae Lee, Jae Seon Eo, Kisoo Pahk, Jae Gol Choe, and Sungeun Kim declare that they have no conflict of interest.

Ethical Statement

This study protocol was approved by the International Review Board for Research on Human Subjects at our hospital. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was waived.

The manuscript has not been published before and is not under consideration for publication anywhere else and has been approved by all coauthors.

References

  1. 1.
    van Meerbeeck JP, Fennell DA, De Ruysscher DK. Small-cell lung cancer. Lancet. 2011;378:1741–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Korea National Cancer Information Center. Annual report of cancer statistics in Korea in 2012. http://www.cancer.go.kr/. Accessed 15 Jun 2015.
  3. 3.
    Johnson BE, Janne PA. Basic treatment considerations using chemotherapy for patients with small cell lung cancer. Hematol Oncol Clin N Am. 2004;18:309–22.CrossRefGoogle Scholar
  4. 4.
    Alexandrakis MG, Passam FH, Kyriakou DS, Dambaki K, Niniraki M, Stathopoulos E. Ki-67 proliferation index: correlation with prognostic parameters and outcome in multiple myeloma. Am J Clin Oncol. 2004;27:8–13.CrossRefPubMedGoogle Scholar
  5. 5.
    Li R, Heydon K, Hammond ME, Grignon DJ, Roach 3rd M, Wolkov HB, et al. Ki-67 staining index predicts distant metastasis and survival in locally advanced prostate cancer treated with radiotherapy: an analysis of patients in radiation therapy oncology group protocol 86–10. Clin Cancer Res. 2004;10:4118–24.CrossRefPubMedGoogle Scholar
  6. 6.
    Stuart-Harris R, Caldas C, Pinder SE, Pharoah P. Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients. Breast. 2008;17:323–34.CrossRefPubMedGoogle Scholar
  7. 7.
    Martin B, Paesmans M, Mascaux C, Berghmans T, Lothaire P, Meert AP, et al. Ki-67 expression and patient’s survival in lung cancer: systematic review of the literature with meta-analysis. Br J Cancer. 2004;91:2018–25.PubMedCentralCrossRefPubMedGoogle Scholar
  8. 8.
    Rohren EM, Turkington TG, Coleman RE. Clinical applications of PET in oncology. Radiology. 2004;231:305–32.CrossRefPubMedGoogle Scholar
  9. 9.
    Zhu D, Ma T, Niu Z, Zheng J, Han A, Zhao S, et al. Prognostic significance of metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer. Lung Cancer. 2011;73:332–7.CrossRefPubMedGoogle Scholar
  10. 10.
    Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, et al. Volume-based parameter of 18F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol. 2010;17:2787–94.CrossRefPubMedGoogle Scholar
  11. 11.
    Xie P, Yue JB, Zhao HX, Sun XD, Kong L, Fu Z, et al. Prognostic value of 18F-FDG PET-CT metabolic index for nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 2010;136:883–9.CrossRefPubMedGoogle Scholar
  12. 12.
    Li YM, Lin Q, Zhao L, Wang LC, Sun L, Dai MM, et al. Pre-treatment metabolic tumor volume and total lesion glycolysis are useful prognostic factors for esophageal squamous cell cancer patients. Asian Pac J Cancer Prev. 2014;15:1369–73.CrossRefPubMedGoogle Scholar
  13. 13.
    Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, et al. Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2007;34:1610–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Vesselle H, Salskov A, Turcotte E, Wiens L, Schmidt R, Jordan CD, et al. Relationship between non-small cell lung cancer FDG uptake at PET, tumor histology, and Ki-67 proliferation index. J Thorac Oncol. 2008;3:971–8.CrossRefPubMedGoogle Scholar
  15. 15.
    Han B, Lin S, Yu LJ, Wang RZ, Wang YY. Correlation of 18F-FDG PET activity with expressions of survivin, Ki67, and CD34 in non-small-cell lung cancer. Nucl Med Commun. 2009;30:831–7.CrossRefPubMedGoogle Scholar
  16. 16.
    Huang W, Zhou T, Ma L, Sun H, Gong H, Wang J, et al. Standard uptake value and metabolic tumor volume of 18F-FDG PET/CT predict short-term outcome early in the course of chemoradiotherapy in advanced non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2011;38:1628–35.CrossRefPubMedGoogle Scholar
  17. 17.
    Ciernik IF, Dizendorf E, Baumert BG, Reiner B, Burger C, Davis JB, et al. Radiation treatment planning with an integrated positron emission and computer tomography (PET/CT): a feasibility study. Int J Radiat Oncol Biol Phys. 2003;57:853–63.CrossRefPubMedGoogle Scholar
  18. 18.
    Lee P, Weerasuriya DK, Lavori PW, Quon A, Hara W, Maxim PG, et al. Metabolic tumor burden predicts for disease progression and death in lung cancer. Int J Radiat Oncol Biol Phys. 2007;69:328–33.CrossRefPubMedGoogle Scholar
  19. 19.
    Dingemans AM, Witlox MA, Stallaert RA, van der Valk P, Postmus PE, Giaccone G. Expression of DNA topoisomerase IIalpha and topoisomerase IIbeta genes predicts survival and response to chemotherapy in patients with small cell lung cancer. Clin Cancer Res. 1999;5:2048–58.PubMedGoogle Scholar
  20. 20.
    Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol. 1984;133:1710–5.PubMedGoogle Scholar
  21. 21.
    Cummings TJ, Provenzale JM, Hunter SB, Friedman AH, Klintworth GK, Bigner SH, et al. Gliomas of the optic nerve: histological, immunohistochemical (MIB-1 and p53), and MRI analysis. Acta Neuropathol. 2000;99:563–70.CrossRefPubMedGoogle Scholar
  22. 22.
    Zlotta AR, Schulman CC. Biological markers in superficial bladder tumors and their prognostic significance. Urol Clin N Am. 2000;27:179–89. xi-xii.CrossRefGoogle Scholar
  23. 23.
    Indinnimeo M, Cicchini C, Stazi A, Limiti MR, Ghini C, Mingazzini P, et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res. 2000;19:471–5.PubMedGoogle Scholar
  24. 24.
    Jakobsen JN, Sorensen JB. Clinical impact of ki-67 labeling index in non-small cell lung cancer. Lung Cancer. 2013;79:1–7.CrossRefPubMedGoogle Scholar
  25. 25.
    Yap CS, Czernin J, Fishbein MC, Cameron RB, Schiepers C, Phelps ME, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography. Chest. 2006;129:393–401.CrossRefPubMedGoogle Scholar
  26. 26.
    Watanabe K, Nomori H, Ohtsuka T, Naruke T, Ebihara A, Orikasa H, et al. [F-18]fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas. Jpn J Clin Oncol. 2006;36:403–9.CrossRefPubMedGoogle Scholar
  27. 27.
    Nguyen XC, Lee WW, Chung JH, Park SY, Sung SW, Kim YK, et al. FDG uptake, glucose transporter type 1, and Ki-67 expressions in non-small-cell lung cancer: correlations and prognostic values. Eur J Radiol. 2007;62:214–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Yang W, Zhang Y, Fu Z, Yu J, Sun X, Mu D, et al. Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 2010;37:1291–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 2003;44:1426–31.PubMedGoogle Scholar
  30. 30.
    Kaira K, Serizawa M, Koh Y, Takahashi T, Hanaoka H, Oriuchi N, et al. Relationship between 18F-FDG uptake on positron emission tomography and molecular biology in malignant pleural mesothelioma. Eur J Cancer. 2012;48:1244–54.CrossRefPubMedGoogle Scholar
  31. 31.
    Inwald EC, Klinkhammer-Schalke M, Hofstadter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539–52.PubMedCentralCrossRefPubMedGoogle Scholar
  32. 32.
    Tabata K, Tanaka T, Hayashi T, Hori T, Nunomura S, Yonezawa S, et al. Ki-67 is a strong prognostic marker of non-small cell lung cancer when tissue heterogeneity is considered. BMC Clin Pathol. 2014;14:23.PubMedCentralCrossRefPubMedGoogle Scholar
  33. 33.
    Reymen B, Van Loon J, van Baardwijk A, Wanders R, Borger J, Dingemans AM, et al. Total gross tumor volume is an independent prognostic factor in patients treated with selective nodal irradiation for stage I to III small cell lung cancer. Int J Radiat Oncol Biol Phys. 2013;85:1319–24.CrossRefPubMedGoogle Scholar
  34. 34.
    Pelosi G, Rodriguez J, Viale G, Rosai J. Typical and atypical pulmonary carcinoid tumor overdiagnosed as small-cell carcinoma on biopsy specispecimens: a major pitfall in the management of lung cancer patients. Am J Surg Pathol. 2005;29:179–87.CrossRefPubMedGoogle Scholar
  35. 35.
    Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, et al. Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 ‘clinically aggressive’ cases. Ann Oncol. 2010;21:548–55.CrossRefPubMedGoogle Scholar
  36. 36.
    Bohm J, Koch S, Gais P, Jutting U, Prauer H, Hofler H. Prognostic value of MIB-1 in neuroendocrine tumours of the lung. J Pathol. 1996;178:402–9.CrossRefPubMedGoogle Scholar
  37. 37.
    Arbiser Z, Arbiser J, Cohen C, Gal A. Neuroendocrine lung tumors: grade correlates with proliferation but not angiogenesis. Mod Pathol. 2001;14:1195–9.CrossRefPubMedGoogle Scholar

Copyright information

© Korean Society of Nuclear Medicine 2015

Authors and Affiliations

  • Soyeon Park
    • 1
  • Eunsub Lee
    • 1
  • Seunghong Rhee
    • 2
  • Jaehyuk Cho
    • 2
  • Sunju Choi
    • 2
  • Sinae Lee
    • 3
  • Jae Seon Eo
    • 1
  • Kisoo Pahk
    • 2
    • 4
  • Jae Gol Choe
    • 2
  • Sungeun Kim
    • 2
    Email author
  1. 1.Department of Nuclear MedicineKorea University Guro HospitalSeoulSouth Korea
  2. 2.Department of Nuclear MedicineKorea University Anam HospitalSeoulSouth Korea
  3. 3.Department of Nuclear MedicineG Sam HospitalGunpoSouth Korea
  4. 4.Department of Neuroscience, College of MedicineKorea UniversitySeoulSouth Korea

Personalised recommendations